Clinical Trial: A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07642050) titled 'A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy' on June 08.

Brief Summary: The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: IgA Nephropathy

Intervention: DRUG: BHV-1400

500 mg delivered subcutaneously via autoinjector

DRUG: Placebo

Matching placebo delivered subcutaneously via autoinjector

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Biohaven Therapeutics Ltd.

Publis...